Trial Title:
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
NCT ID:
NCT05564403
Condition:
Advanced Biliary Tract Carcinoma
Advanced Gallbladder Carcinoma
Advanced Intrahepatic Cholangiocarcinoma
Recurrent Biliary Tract Carcinoma
Recurrent Gallbladder Carcinoma
Recurrent Intrahepatic Cholangiocarcinoma
Stage III Distal Bile Duct Cancer AJCC v8
Stage III Gallbladder Cancer AJCC v8
Stage III Hilar Cholangiocarcinoma AJCC v8
Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Stage IV Distal Bile Duct Cancer AJCC v8
Stage IV Gallbladder Cancer AJCC v8
Stage IV Hilar Cholangiocarcinoma AJCC v8
Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Unresectable Biliary Tract Carcinoma
Unresectable Gallbladder Carcinoma
Unresectable Intrahepatic Cholangiocarcinoma
Conditions: Official terms:
Carcinoma
Cholangiocarcinoma
Biliary Tract Neoplasms
Gallbladder Neoplasms
Bile Duct Neoplasms
Klatskin Tumor
Recurrence
Calcium, Dietary
Leucovorin
Folic Acid
Oxaliplatin
Fluorouracil
Calcium
Levoleucovorin
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Binimetinib
Description:
Given PO
Arm group label:
Arm 2 (binimetinib, mFOLFOX6)
Other name:
ARRY 162
Other name:
ARRY 438162
Other name:
ARRY-162
Other name:
ARRY-438162
Other name:
ARRY162
Other name:
ARRY438162
Other name:
MEK 162
Other name:
MEK-162
Other name:
MEK162
Other name:
Mektovi
Intervention type:
Procedure
Intervention name:
Biopsy
Description:
Undergo biopsy
Arm group label:
Arm 1 (mFOLFOX6)
Arm group label:
Arm 2 (binimetinib, mFOLFOX6)
Other name:
BIOPSY_TYPE
Other name:
Bx
Intervention type:
Procedure
Intervention name:
Biospecimen Collection
Description:
Undergo collection of blood
Arm group label:
Arm 1 (mFOLFOX6)
Arm group label:
Arm 2 (binimetinib, mFOLFOX6)
Other name:
Biological Sample Collection
Other name:
Biospecimen Collected
Other name:
Specimen Collection
Intervention type:
Procedure
Intervention name:
Bone Scan
Description:
Undergo bone scan
Arm group label:
Arm 1 (mFOLFOX6)
Arm group label:
Arm 2 (binimetinib, mFOLFOX6)
Other name:
Bone Scintigraphy
Intervention type:
Procedure
Intervention name:
Computed Tomography
Description:
Undergo CT
Arm group label:
Arm 1 (mFOLFOX6)
Arm group label:
Arm 2 (binimetinib, mFOLFOX6)
Other name:
CAT
Other name:
CAT Scan
Other name:
Computed Axial Tomography
Other name:
Computerized Axial Tomography
Other name:
Computerized axial tomography (procedure)
Other name:
Computerized Tomography
Other name:
Computerized Tomography (CT) scan
Other name:
CT
Other name:
CT Scan
Other name:
tomography
Intervention type:
Procedure
Intervention name:
Echocardiography
Description:
Undergo ECHO
Arm group label:
Arm 2 (binimetinib, mFOLFOX6)
Other name:
EC
Intervention type:
Drug
Intervention name:
Fluorouracil
Description:
Given IV
Arm group label:
Arm 1 (mFOLFOX6)
Arm group label:
Arm 2 (binimetinib, mFOLFOX6)
Other name:
5 Fluorouracil
Other name:
5 Fluorouracilum
Other name:
5 FU
Other name:
5-Fluoro-2,4(1H, 3H)-pyrimidinedione
Other name:
5-Fluorouracil
Other name:
5-Fluracil
Other name:
5-Fu
Other name:
5FU
Other name:
AccuSite
Other name:
Carac
Other name:
Fluoro Uracil
Other name:
Fluouracil
Other name:
Flurablastin
Other name:
Fluracedyl
Other name:
Fluracil
Other name:
Fluril
Other name:
Fluroblastin
Other name:
Ribofluor
Other name:
Ro 2-9757
Other name:
Ro-2-9757
Intervention type:
Drug
Intervention name:
Leucovorin Calcium
Description:
Given IV
Arm group label:
Arm 1 (mFOLFOX6)
Arm group label:
Arm 2 (binimetinib, mFOLFOX6)
Other name:
Adinepar
Other name:
Calcifolin
Other name:
Calcium (6S)-Folinate
Other name:
Calcium Folinate
Other name:
Calcium Leucovorin
Other name:
Calfolex
Other name:
Calinat
Other name:
Cehafolin
Other name:
Citofolin
Other name:
Citrec
Other name:
Citrovorum Factor
Other name:
Cromatonbic Folinico
Other name:
Dalisol
Other name:
Disintox
Other name:
Divical
Other name:
Ecofol
Other name:
Emovis
Other name:
Factor, Citrovorum
Other name:
Flynoken A
Other name:
Folaren
Other name:
Folaxin
Other name:
FOLI-cell
Other name:
Foliben
Other name:
Folidan
Other name:
Folidar
Other name:
Folinac
Other name:
Folinate Calcium
Other name:
folinic acid
Other name:
Folinic Acid Calcium Salt Pentahydrate
Other name:
Folinoral
Other name:
Folinvit
Other name:
Foliplus
Other name:
Folix
Other name:
Imo
Other name:
Lederfolat
Other name:
Lederfolin
Other name:
Leucosar
Other name:
leucovorin
Other name:
Rescufolin
Other name:
Rescuvolin
Other name:
Tonofolin
Other name:
Wellcovorin
Intervention type:
Procedure
Intervention name:
Magnetic Resonance Imaging
Description:
Undergo MRI
Arm group label:
Arm 1 (mFOLFOX6)
Arm group label:
Arm 2 (binimetinib, mFOLFOX6)
Other name:
Magnetic Resonance
Other name:
Magnetic Resonance Imaging (MRI)
Other name:
Magnetic resonance imaging (procedure)
Other name:
Magnetic Resonance Imaging Scan
Other name:
Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
Other name:
MR
Other name:
MR Imaging
Other name:
MRI
Other name:
MRI Scan
Other name:
MRIs
Other name:
NMR Imaging
Other name:
NMRI
Other name:
Nuclear Magnetic Resonance Imaging
Other name:
sMRI
Other name:
Structural MRI
Intervention type:
Procedure
Intervention name:
Multigated Acquisition Scan
Description:
Undergo MUGA
Arm group label:
Arm 2 (binimetinib, mFOLFOX6)
Other name:
Blood Pool Scan
Other name:
Equilibrium Radionuclide Angiography
Other name:
Gated Blood Pool Imaging
Other name:
Gated Heart Pool Scan
Other name:
MUGA
Other name:
MUGA Scan
Other name:
Multi-Gated Acquisition Scan
Other name:
Radionuclide Ventriculogram Scan
Other name:
Radionuclide Ventriculography
Other name:
RNV Scan
Other name:
RNVG
Other name:
SYMA Scanning
Other name:
Synchronized Multigated Acquisition Scanning
Intervention type:
Drug
Intervention name:
Oxaliplatin
Description:
Given IV
Arm group label:
Arm 1 (mFOLFOX6)
Arm group label:
Arm 2 (binimetinib, mFOLFOX6)
Other name:
1-OHP
Other name:
Ai Heng
Other name:
Aiheng
Other name:
Dacotin
Other name:
Dacplat
Other name:
Diaminocyclohexane Oxalatoplatinum
Other name:
Eloxatin
Other name:
Eloxatine
Other name:
Elplat
Other name:
JM 83
Other name:
JM-83
Other name:
JM83
Other name:
Oxalatoplatin
Other name:
Oxalatoplatinum
Other name:
RP 54780
Other name:
RP-54780
Other name:
RP54780
Other name:
SR 96669
Other name:
SR-96669
Other name:
SR96669
Summary:
This phase II ComboMATCH treatment trial compares the usual treatment of modified
leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib
plus mFOLFOX6 chemotherapy to shrink tumors in patients with biliary tract cancers that
have spread to other places in the body (advanced) and had progression of cancer after
previous treatments (2nd line setting). Fluorouracil is in a class of medications called
antimetabolites. It works by slowing or stopping the growth of cancer cells in the body.
Oxaliplatin is in a class of medications called platinum-containing antineoplastic
agents. It works by killing tumor cells. Leucovorin may help the other drugs in the
mFOLFOX6 chemotherapy regimen work better by making tumor cells more sensitive to the
drugs. Binimetinib is in a class of medications called kinase inhibitors. It works by
blocking the action of the abnormal protein that signals tumor cells to multiply. This
helps to stop or slow the spread of tumor cells. Giving binimetinib in combination with
mFOLFOX6 chemotherapy may be effective in shrinking or stabilizing advanced biliary tract
cancers in the 2nd line setting.
Detailed description:
PRIMARY OBJECTIVE:
I. To determine whether binimetinib and mFOLFOX6 combination therapy improves overall
survival (OS) compared to mFOLFOX6 alone in patients with advanced/recurrent biliary
tract cancer (BTC) and with alterations in RAS/RAF/MEK/ERK pathway, who have progressed
on one prior line of therapy.
SECONDARY OBJECTIVES:
I. To determine whether binimetinib and mFOLFOX6 combination therapy improves objective
response rate (ORR) compared to FOLFOX alone.
II. To determine if clinical outcomes including progression free survival (PFS), duration
of response (DOR), and disease control rate (DCR) are improved with combination treatment
of binimetinib and mFOLFOX6 compared to FOLFOX alone in patients with advanced/recurrent
BTC and with alterations in RAS/RAF/MEK/ERK pathway who have progression on one prior
line of therapy.
III. Toxicity and tolerability will be evaluated within and between the two treatment
arms, where frequency, type, and severity of adverse events will be assessed per the
National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
version (v)5.0.
IV. Collect tissue and provide it to the ComboMATCH Registration Protocol to assess
concordance between the diagnostic tumor mutation profile generated by the Designated
Laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment
circulating tumor deoxyribonucleic acid (ctDNA) mutation profile from plasma, as
described in ComboMATCH Registration Protocol.
EXPLORATORY OBJECTIVES:
I. Generate a prognostic model of MAPK mutations for this patient population using
clinical, laboratory and molecular features of their disease and clinical outcome to
validate on future samples.
II. Correlation of outcome with albumin. III. Assess the correlation between the presence
of MAPK pathway mutations and activity of addition of binimetinib therapy to standard 2nd
line chemotherapy.
IV. Conduct whole-exome sequencing and ribonucleic acid (RNA)-sequencing at baseline, and
on optional biopsy upon progression to assess determinants of response and resistance.
V. Explore changes in plasma MAPK mutations allelic burden and other molecular findings
at baseline and upon progression using ctDNA and correlate changes with clinical
activity, disease course as well as response/resistance to therapy.
VI. Evaluate if our machine learning algorithm for RAS/RAF/MEK/ERK pathway mutations
correlates with detection of mutations as well as prediction of outcomes from samples
obtained in this study.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive leucovorin intravenously (IV) over 2 hours and oxaliplatin IV
over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Cycles repeat
every 14 days in the absence of disease progression or unacceptable toxicity. Patients
undergo collection of blood during screening and on study, and undergo computed
tomography (CT) with contrast, magnetic resonance imaging (MRI), or fludeoxyglucose F-18
positron emission tomography (FDG-PET) throughout the trial as clinically indicated.
Patients may also undergo bone scans on study and may undergo biopsies throughout the
study as clinically indicated.
ARM 2: Patients receive binimetinib orally (PO) on days 1-14, and leucovorin IV,
oxaliplatin IV, and fluorouracil IV as in Arm 1. Cycles repeat every 14 days in the
absence of disease progression or unacceptable toxicity. Patients undergo echocardiogram
(ECHO) or multigated acquisition scan (MUGA) and collection of blood during screening and
on study, and undergo CT with contrast, MRI, or FDG-PET throughout the trial as
clinically indicated. Patients may also undergo bone scans on study and may undergo
biopsies throughout the study as clinically indicated.
After completion of study treatment, patients are followed up every 8 weeks until disease
progression, thereafter patients are followed for survival every 4 months for up to 5
years following registration.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Patient must have enrolled onto EAY191 and must have been given a treatment
assignment to ComboMATCH to EAY191-A6 based on the presence of an actionable
mutation as defined in EAY191
- GENERAL COMBOMATCH EAY191:
- Patients must be registered to the ComboMATCH Registration Protocol (EAY191)
- Patients must have RAS/RAF/MEK/ERK mutations as determined by the ComboMATCH
screening assessment
- Patients must not have BRAF V600E as determined by the ComboMATCH screening
assessment
- Patients must have disease that can be safely biopsied and agree to a pre-treatment
biopsy or have archival tissue available from within 12 months prior to registration
on the ComboMATCH Registration Trial (EAY191).
- Please note the current actionable marker of interest (aMOI)/actionable alteration
list for this treatment trial can be found on the Cancer Trials Support Unit (CTSU)
website
- Please note novel/Dynamic aMOI can be submitted for review per the process described
in the ComboMATCH Registration Protocol
- EAY191-A6 REGISTRATION:
- Participants must have histologically confirmed BTC (intrahepatic cholangiocarcinoma
[IHC], extrahepatic cholangiocarcinoma [EHC] or gallbladder cancer [GBC]) that is
unresectable or recurrent with a confirmed RAS/RAF/MEK/ERK pathway mutation via any
Clinical Laboratory Improvement Act (CLIA)-certified method. BRAFV600E mutations are
not eligible due to other ongoing/upcoming studies in this disease cohort
- Tumor tissue must be available:
- Adequate archival tumor specimen (obtained within 12 months of EAY191
registration which has not had a Response Evaluation Criteria in Solid Tumors
(RECIST) response, complete response (CR) or partial response (PR), to any
intervening therapy after collection of the tissue) must be available with
formalin-fixed paraffin-embedded tumor tissue (blocks or slides) OR
- Consent to a new tumor tissue biopsy which is not a representative target
lesion. This lesion must be amenable to a minimal risk image-guided or direct
vision biopsy
- A new biopsy is preferred but is not required for enrollment in EAY191-A6
if sufficient archival tissue is available as described above.
- Measurable disease per RECIST 1.1 Of note, in the case when a baseline biopsy is
done after scans are obtained, a lesion separate from one that is biopsied needs to
be measurable per RECIST 1.1. All radiologic studies must be performed within 28
days prior to registration
- Progression of disease on gemcitabine based first-line regimen (i.e. only one prior
line of therapy is permitted)
- No systemic anti-cancer therapy within 4 weeks of registration to EAY191-A6
- No prior MEK inhibitor therapy
- No prior history of treatment with a direct and specific inhibitor of KRAS
- Patients who only received radio-sensitizing chemotherapy with fluorouracil (5-FU)
or capecitabine are eligible, but need to have received and failed first-line
systemic chemotherapy upon recurrence. Peri-operative systemic 5-FU/capecitabine
and/or oxaliplatin, is allowed if it's been more than 12 months of registration to
EAY191-A6
- No major surgery within 4 weeks (excluding placement of vascular access) of
registration to EAY191-A6
- No minor surgery within 2 weeks of registration to EAY191-A6
- No palliative radiotherapy within 1 week of registration to EAY191-A6
- Not pregnant and not nursing, because this study involves an investigational agent
whose genotoxic, mutagenic and teratogenic effects on the developing fetus and
newborn are unknown
- Therefore, for women of childbearing potential only, a negative pregnancy test
done =< 14 days prior to registration is required
- Adequate contraception is needed for at least 30 days after the last dose of
binimetinib and breastfeeding should be discontinued for at least 3 days after
the last dose of binimetinib. For FOLFOX regimen, 9 months is recommended for
contraception after last dose of oxaliplatin for females of childbearing
potential and 6 months for males
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Absolute neutrophil count (ANC) >= 1,000/mm^3, no growth factor within 14 days of
1st dose
- Platelet count >= 75,000/mm^3
- Creatinine < 1.6 x upper limit of normal (ULN) OR
- Calculated (Calc.) creatinine clearance >= 50 mL/min, as calculated by the
Cockcroft-Gault formula
- Total bilirubin =< 2.0 x upper limit of normal (ULN); Patients with Gilbert syndrome
may enroll if < 3.0 x ULN
- Aspartate aminotransferase (AST) /alanine aminotransferase (ALT) =< 5.0 x upper
limit of normal (ULN)
- Hemoglobin >= 8 g/dL, no transfusion within 7 days of 1st dose
- Creatine phosphokinase =< 2.5 x ULN
- High blood pressure more than 160/90 despite treatment are ineligible
- No history of interstitial lung disease. No history of idiopathic pulmonary
fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced
pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on
screening chest computed tomography (CT) scan
- Patients should not have history of bowel perforation or intestinal fistulas in the
last 6 months
- Patients with the inability to swallow oral medications or impaired gastrointestinal
absorption due to gastrectomy or active inflammatory bowel disease are ineligible
- Must have adequate cardiac function with left ventricular ejection fraction >= 50%
by echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan. Patients with
congenital long QT syndrome are not permitted
- No history of prolonged QTc or at risk for prolonged QTc due to any reason (for
example, concomitant medications during or before chemotherapy that may increase the
risk of prolonged QTc), uncontrolled congestive heart failure, prior history of
class III/ IV cardiac disease (New York Heart Association [NYHA]), myocardial
infarction within the last 6 months, unstable arrhythmias, unstable angina or severe
obstructive pulmonary disease
- No active skin disorder that has required systemic therapy within the past 1 year
- No history of rhabdomyolysis
- No concurrent ocular disorders, including:
- Patients with history of glaucoma, history of retinal vein occlusion (RVO),
predisposing factors for RVO, including but not limited to uncontrolled
hypertension, uncontrolled diabetes
- Patients with history of retinal pathology or evidence of visible retinal
pathology that is considered a risk factor for RVO, intraocular pressure > 21
mm Hg as measured by tonometry, or other significant ocular pathology, such as
anatomical abnormalities that increase the risk for RVO
- Patients with a history of corneal erosion (instability of corneal epithelium),
corneal degeneration, active or recurrent keratitis, and other forms of serious
ocular surface inflammatory conditions
- Patients with known or at risk for retinopathies, uveitis or retinal vein
occlusion
- No patients with a history of hypersensitivity to any of the inactive ingredients in
binimetinib, nor known severe allergic reactions or hypersensitivity of 5-FU,
leucovorin (LV) or oxaliplatin will be allowed to participate in this study for
safety concerns
- No other medical condition (e.g. cardiac, gastrointestinal, pulmonary, psychiatric,
neurological, genetic, etc.) that in the opinion of the investigator would places
the subject at unacceptably high risk for toxicity
- No prior allogeneic stem cell or solid organ transplantation
- Central nervous system (CNS) metastases must have been treated with local therapy
(surgery, radiation, ablation) with systemic steroids tapered to a physiologic dose
(10 mg or prednisone equivalent or less)
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral
therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV
viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated
and cured. For patients with HCV infection who are currently on treatment, they are
eligible if they have an undetectable HCV viral load
- Patients must not have grade 2 neuropathy or greater, within 14 days prior to
registration
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
University of Alabama at Birmingham Cancer Center
Address:
City:
Birmingham
Zip:
35233
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
205-934-0220
Email:
tmyrick@uab.edu
Investigator:
Last name:
Rebecca C. Arend
Email:
Principal Investigator
Facility:
Name:
University of South Alabama Mitchell Cancer Institute
Address:
City:
Mobile
Zip:
36688
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
251-445-9870
Email:
pfrancisco@usouthal.edu
Investigator:
Last name:
Ahmed Abdalla
Email:
Principal Investigator
Facility:
Name:
Mayo Clinic Hospital in Arizona
Address:
City:
Phoenix
Zip:
85054
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
855-776-0015
Investigator:
Last name:
Lionel Aurelien Kankeu Fonkoua
Email:
Principal Investigator
Facility:
Name:
Presbyterian Intercommunity Hospital
Address:
City:
Whittier
Zip:
90602
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
562-698-0811
Investigator:
Last name:
Christopher R. Foss
Email:
Principal Investigator
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Aventura
Address:
City:
Aventura
Zip:
33180
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
954-461-2180
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Coral Gables
Address:
City:
Coral Gables
Zip:
33146
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
305-243-2647
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Address:
City:
Deerfield Beach
Zip:
33442
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
305-243-2647
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
Mayo Clinic in Florida
Address:
City:
Jacksonville
Zip:
32224-9980
Country:
United States
Status:
Suspended
Facility:
Name:
University of Miami Miller School of Medicine-Sylvester Cancer Center
Address:
City:
Miami
Zip:
33136
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
305-243-2647
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Kendall
Address:
City:
Miami
Zip:
33176
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
305-243-2647
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
UM Sylvester Comprehensive Cancer Center at Plantation
Address:
City:
Plantation
Zip:
33324
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
305-243-2647
Investigator:
Last name:
Chukwuemeka (Emeka) V. Ikpeazu
Email:
Principal Investigator
Facility:
Name:
Hawaii Cancer Care - Westridge
Address:
City:
'Aiea
Zip:
96701
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
808-539-2273
Email:
info@hawaiicancercare.com
Investigator:
Last name:
Jared D. Acoba
Email:
Principal Investigator
Facility:
Name:
The Queen's Medical Center - West Oahu
Address:
City:
'Ewa Beach
Zip:
96706
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
rohta@queens.org
Investigator:
Last name:
Jared D. Acoba
Email:
Principal Investigator
Facility:
Name:
Hawaii Cancer Care Inc - Waterfront Plaza
Address:
City:
Honolulu
Zip:
96813
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
808-524-6115
Email:
i.webster@hawaiicancercare.com
Investigator:
Last name:
Jared D. Acoba
Email:
Principal Investigator
Facility:
Name:
Queen's Cancer Cenrer - POB I
Address:
City:
Honolulu
Zip:
96813
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
808-532-0315
Investigator:
Last name:
Jared D. Acoba
Email:
Principal Investigator
Facility:
Name:
Queen's Medical Center
Address:
City:
Honolulu
Zip:
96813
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
808-545-8548
Investigator:
Last name:
Jared D. Acoba
Email:
Principal Investigator
Facility:
Name:
Queen's Cancer Center - Kuakini
Address:
City:
Honolulu
Zip:
96817
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
808-531-8521
Investigator:
Last name:
Jared D. Acoba
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Boise
Address:
City:
Boise
Zip:
83706
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-3671
Email:
stephanie.couch@stjoeshealth.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Boise
Address:
City:
Boise
Zip:
83712
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Caldwell
Address:
City:
Caldwell
Zip:
83605
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-3671
Email:
stephanie.couch@stjoeshealth.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Health - Coeur d'Alene
Address:
City:
Coeur d'Alene
Zip:
83814
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Fruitland
Address:
City:
Fruitland
Zip:
83619
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Meridian
Address:
City:
Meridian
Zip:
83642
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Nampa
Address:
City:
Nampa
Zip:
83687
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Nampa
Address:
City:
Nampa
Zip:
83687
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Post Falls
Address:
City:
Post Falls
Zip:
83854
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Sandpoint
Address:
City:
Sandpoint
Zip:
83864
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Advocate Good Shepherd Hospital
Address:
City:
Barrington
Zip:
60010
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
847-842-4847
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Northwestern University
Address:
City:
Chicago
Zip:
60611
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
312-695-1301
Email:
cancer@northwestern.edu
Investigator:
Last name:
Aparna Kalyan
Email:
Principal Investigator
Facility:
Name:
John H Stroger Jr Hospital of Cook County
Address:
City:
Chicago
Zip:
60612
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
312-864-5204
Investigator:
Last name:
Thomas E. Lad
Email:
Principal Investigator
Facility:
Name:
University of Chicago Comprehensive Cancer Center
Address:
City:
Chicago
Zip:
60637
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
773-702-8222
Email:
cancerclinicaltrials@bsd.uchicago.edu
Investigator:
Last name:
Chih-Yi Liao
Email:
Principal Investigator
Facility:
Name:
Advocate Illinois Masonic Medical Center
Address:
City:
Chicago
Zip:
60657
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
773-296-5360
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
AMG Crystal Lake - Oncology
Address:
City:
Crystal Lake
Zip:
60014
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-929-6129
Email:
advocateresearch@advocate.com
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Carle at The Riverfront
Address:
City:
Danville
Zip:
61832
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@Carle.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Cancer Care Specialists of Illinois - Decatur
Address:
City:
Decatur
Zip:
62526
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Decatur Memorial Hospital
Address:
City:
Decatur
Zip:
62526
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Advocate Good Samaritan Hospital
Address:
City:
Downers Grove
Zip:
60515
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-275-1270
Email:
Barbara.barhamand@advocatehealth.com
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Carle Physician Group-Effingham
Address:
City:
Effingham
Zip:
62401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Crossroads Cancer Center
Address:
City:
Effingham
Zip:
62401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Advocate Sherman Hospital
Address:
City:
Elgin
Zip:
60123
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
847-429-2907
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Advocate South Suburban Hospital
Address:
City:
Hazel Crest
Zip:
60429
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
708-799-9995
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
AMG Libertyville - Oncology
Address:
City:
Libertyville
Zip:
60048
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-929-6129
Email:
advocateresearch@advocatehealth.com
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Condell Memorial Hospital
Address:
City:
Libertyville
Zip:
60048
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-929-6129
Email:
advocateresearch@advocatehealth.com
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Carle Physician Group-Mattoon/Charleston
Address:
City:
Mattoon
Zip:
61938
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
UC Comprehensive Cancer Center at Silver Cross
Address:
City:
New Lenox
Zip:
60451
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
773-702-8222
Email:
cancerclinicaltrials@bsd.uchicago.edu
Investigator:
Last name:
Chih-Yi Liao
Email:
Principal Investigator
Facility:
Name:
Cancer Care Center of O'Fallon
Address:
City:
O'Fallon
Zip:
62269
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Advocate Christ Medical Center
Address:
City:
Oak Lawn
Zip:
60453-2699
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-323-8622
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
University of Chicago Medicine-Orland Park
Address:
City:
Orland Park
Zip:
60462
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
773-702-8222
Email:
cancerclinicaltrials@bsd.uchicago.edu
Investigator:
Last name:
Chih-Yi Liao
Email:
Principal Investigator
Facility:
Name:
Advocate Lutheran General Hospital
Address:
City:
Park Ridge
Zip:
60068
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
847-384-3621
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Memorial Hospital East
Address:
City:
Shiloh
Zip:
62269
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-747-9912
Email:
dschwab@wustl.edu
Investigator:
Last name:
Olivia Aranha
Email:
Principal Investigator
Facility:
Name:
Southern Illinois University School of Medicine
Address:
City:
Springfield
Zip:
62702
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-545-7929
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Springfield Clinic
Address:
City:
Springfield
Zip:
62702
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-444-7541
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Springfield Memorial Hospital
Address:
City:
Springfield
Zip:
62781
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-528-7541
Email:
pallante.beth@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Carle Cancer Center
Address:
City:
Urbana
Zip:
61801
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Mission Cancer and Blood - Ankeny
Address:
City:
Ankeny
Zip:
50023
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-282-2921
Investigator:
Last name:
Seema Harichand-Herdt
Email:
Principal Investigator
Facility:
Name:
Mission Cancer and Blood - Des Moines
Address:
City:
Des Moines
Zip:
50309
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-241-3305
Investigator:
Last name:
Seema Harichand-Herdt
Email:
Principal Investigator
Facility:
Name:
University of Kentucky/Markey Cancer Center
Address:
City:
Lexington
Zip:
40536
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
859-257-3379
Investigator:
Last name:
Susanne M. Arnold
Email:
Principal Investigator
Facility:
Name:
Lafayette Family Cancer Center-EMMC
Address:
City:
Brewer
Zip:
04412
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-987-3005
Investigator:
Last name:
Sarah J. Sinclair
Email:
Principal Investigator
Facility:
Name:
University of Maryland/Greenebaum Cancer Center
Address:
City:
Baltimore
Zip:
21201
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-888-8823
Investigator:
Last name:
Ranee Mehra
Email:
Principal Investigator
Facility:
Name:
National Institutes of Health Clinical Center
Address:
City:
Bethesda
Zip:
20892
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-411-1222
Investigator:
Last name:
Jibran Ahmed
Email:
Principal Investigator
Facility:
Name:
UPMC Western Maryland
Address:
City:
Cumberland
Zip:
21502
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
240-964-1400
Investigator:
Last name:
Anwaar Saeed
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Address:
City:
Ann Arbor
Zip:
48106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
University of Michigan Comprehensive Cancer Center
Address:
City:
Ann Arbor
Zip:
48109
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-865-1125
Investigator:
Last name:
Vaibhav Sahai
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Medical Center - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Medical Center - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Corewell Health Dearborn Hospital
Address:
City:
Dearborn
Zip:
48124
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Corewell Health Farmington Hills Hospital
Address:
City:
Farmington Hills
Zip:
48336
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Genesee Cancer and Blood Disease Treatment Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesee Hematology Oncology PC
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesys Hurley Cancer Institute
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Hurley Medical Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
University of Michigan Health - Sparrow Lansing
Address:
City:
Lansing
Zip:
48912
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
517-364-3712
Email:
harsha.trivedi@umhsparrow.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Mary Mercy Livonia Hospital
Address:
City:
Livonia
Zip:
48154
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Henry Ford Saint John Hospital - Macomb Medical
Address:
City:
Macomb
Zip:
48044
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Corewell Health William Beaumont University Hospital
Address:
City:
Royal Oak
Zip:
48073
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Corewell Health Beaumont Troy Hospital
Address:
City:
Troy
Zip:
48085
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Huron Gastroenterology PC
Address:
City:
Ypsilanti
Zip:
48106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Address:
City:
Ypsilanti
Zip:
48197
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Sanford Joe Lueken Cancer Center
Address:
City:
Bemidji
Zip:
56601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-333-5000
Email:
OncologyClinicalTrialsFargo@sanfordhealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
Mercy Hospital
Address:
City:
Coon Rapids
Zip:
55433
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
Daniel M. Anderson
Email:
Principal Investigator
Facility:
Name:
Essentia Health - Deer River Clinic
Address:
City:
Deer River
Zip:
56636
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Essentia Health Cancer Center
Address:
City:
Duluth
Zip:
55805
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Fairview Southdale Hospital
Address:
City:
Edina
Zip:
55435
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
Daniel M. Anderson
Email:
Principal Investigator
Facility:
Name:
Essentia Health Hibbing Clinic
Address:
City:
Hibbing
Zip:
55746
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Abbott-Northwestern Hospital
Address:
City:
Minneapolis
Zip:
55407
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
Daniel M. Anderson
Email:
Principal Investigator
Facility:
Name:
Mayo Clinic in Rochester
Address:
City:
Rochester
Zip:
55905
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
855-776-0015
Investigator:
Last name:
Lionel Aurelien Kankeu Fonkoua
Email:
Principal Investigator
Facility:
Name:
Park Nicollet Clinic - Saint Louis Park
Address:
City:
Saint Louis Park
Zip:
55416
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
Daniel M. Anderson
Email:
Principal Investigator
Facility:
Name:
Regions Hospital
Address:
City:
Saint Paul
Zip:
55101
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
Daniel M. Anderson
Email:
Principal Investigator
Facility:
Name:
United Hospital
Address:
City:
Saint Paul
Zip:
55102
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
Daniel M. Anderson
Email:
Principal Investigator
Facility:
Name:
Essentia Health Sandstone
Address:
City:
Sandstone
Zip:
55072
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Essentia Health Virginia Clinic
Address:
City:
Virginia
Zip:
55792
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Saint Francis Medical Center
Address:
City:
Cape Girardeau
Zip:
63703
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
573-334-2230
Email:
sfmc@sfmc.net
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at West County Hospital
Address:
City:
Creve Coeur
Zip:
63141
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Olivia Aranha
Email:
Principal Investigator
Facility:
Name:
Parkland Health Center - Farmington
Address:
City:
Farmington
Zip:
63640
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-996-5569
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Washington University School of Medicine
Address:
City:
Saint Louis
Zip:
63110
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Olivia Aranha
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center-South County
Address:
City:
Saint Louis
Zip:
63129
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Olivia Aranha
Email:
Principal Investigator
Facility:
Name:
Missouri Baptist Medical Center
Address:
City:
Saint Louis
Zip:
63131
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-996-5569
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at Christian Hospital
Address:
City:
Saint Louis
Zip:
63136
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Olivia Aranha
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at Saint Peters Hospital
Address:
City:
Saint Peters
Zip:
63376
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Olivia Aranha
Email:
Principal Investigator
Facility:
Name:
Sainte Genevieve County Memorial Hospital
Address:
City:
Sainte Genevieve
Zip:
63670
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-996-5569
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Missouri Baptist Sullivan Hospital
Address:
City:
Sullivan
Zip:
63080
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-996-5569
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
BJC Outpatient Center at Sunset Hills
Address:
City:
Sunset Hills
Zip:
63127
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-996-5569
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Community Hospital of Anaconda
Address:
City:
Anaconda
Zip:
59711
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Billings Clinic Cancer Center
Address:
City:
Billings
Zip:
59101
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-996-2663
Email:
research@billingsclinic.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Bozeman Health Deaconess Hospital
Address:
City:
Bozeman
Zip:
59715
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Benefis Sletten Cancer Institute
Address:
City:
Great Falls
Zip:
59405
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Logan Health Medical Center
Address:
City:
Kalispell
Zip:
59901
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Community Medical Center
Address:
City:
Missoula
Zip:
59804
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Nebraska Medicine-Bellevue
Address:
City:
Bellevue
Zip:
68123
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
402-559-6941
Email:
unmcrsa@unmc.edu
Investigator:
Last name:
Mridula Krishnan
Email:
Principal Investigator
Facility:
Name:
Nebraska Medicine-Village Pointe
Address:
City:
Omaha
Zip:
68118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
402-559-5600
Investigator:
Last name:
Mridula Krishnan
Email:
Principal Investigator
Facility:
Name:
University of Nebraska Medical Center
Address:
City:
Omaha
Zip:
68198
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
402-559-6941
Email:
unmcrsa@unmc.edu
Investigator:
Last name:
Mridula Krishnan
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Seven Hills
Address:
City:
Henderson
Zip:
89052
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Charleston
Address:
City:
Las Vegas
Zip:
89102
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Fort Apache
Address:
City:
Las Vegas
Zip:
89148
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
University of New Mexico Cancer Center
Address:
City:
Albuquerque
Zip:
87106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
505-925-0348
Email:
HSC-ClinicalTrialInfo@salud.unm.edu
Investigator:
Last name:
Ursa A. Brown-Glaberman
Email:
Principal Investigator
Facility:
Name:
Sanford Bismarck Medical Center
Address:
City:
Bismarck
Zip:
58501
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
701-323-5760
Email:
OncologyClinicalTrialsFargo@sanfordhealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
Sanford Broadway Medical Center
Address:
City:
Fargo
Zip:
58122
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
701-323-5760
Email:
OncologyClinicalTrialsFargo@sanfordhealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
Sanford Roger Maris Cancer Center
Address:
City:
Fargo
Zip:
58122
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
701-234-6161
Email:
OncologyClinicalTrialsFargo@sanfordhealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
Miami Valley Hospital South
Address:
City:
Centerville
Zip:
45459
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Miami Valley Hospital
Address:
City:
Dayton
Zip:
45409
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Premier Blood and Cancer Center
Address:
City:
Dayton
Zip:
45409
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-276-8320
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Dayton Physician LLC - Englewood
Address:
City:
Dayton
Zip:
45415
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Miami Valley Hospital North
Address:
City:
Dayton
Zip:
45415
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Atrium Medical Center-Middletown Regional Hospital
Address:
City:
Franklin
Zip:
45005-1066
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Miami Valley Cancer Care and Infusion
Address:
City:
Greenville
Zip:
45331
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-569-7515
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
Kettering Medical Center
Address:
City:
Kettering
Zip:
45429
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Upper Valley Medical Center
Address:
City:
Troy
Zip:
45373
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Tarek M. Sabagh
Email:
Principal Investigator
Facility:
Name:
University of Oklahoma Health Sciences Center
Address:
City:
Oklahoma City
Zip:
73104
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
405-271-8777
Email:
ou-clinical-trials@ouhsc.edu
Investigator:
Last name:
Hassan Hatoum
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Ontario
Address:
City:
Ontario
Zip:
97914
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
UPMC Altoona
Address:
City:
Altoona
Zip:
16601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
773-702-9171
Email:
protocols@AllianceNCTN.org
Investigator:
Last name:
Anwaar Saeed
Email:
Principal Investigator
Facility:
Name:
UPMC Hillman Cancer Center Erie
Address:
City:
Erie
Zip:
16505
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-389-5208
Email:
haneydl@upmc.edu
Investigator:
Last name:
Anwaar Saeed
Email:
Principal Investigator
Facility:
Name:
UPMC Cancer Centers - Arnold Palmer Pavilion
Address:
City:
Greensburg
Zip:
15601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
724-838-1900
Investigator:
Last name:
Anwaar Saeed
Email:
Principal Investigator
Facility:
Name:
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
Address:
City:
Mechanicsburg
Zip:
17050
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-389-5208
Email:
haneydl@upmc.edu
Investigator:
Last name:
Anwaar Saeed
Email:
Principal Investigator
Facility:
Name:
UPMC Hillman Cancer Center - Monroeville
Address:
City:
Monroeville
Zip:
15146
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-389-5208
Email:
haneydl@upmc.edu
Investigator:
Last name:
Anwaar Saeed
Email:
Principal Investigator
Facility:
Name:
University of Pittsburgh Cancer Institute (UPCI)
Address:
City:
Pittsburgh
Zip:
15232
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-647-8073
Investigator:
Last name:
Anwaar Saeed
Email:
Principal Investigator
Facility:
Name:
UPMC-Passavant Hospital
Address:
City:
Pittsburgh
Zip:
15237
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
412-367-6454
Investigator:
Last name:
Anwaar Saeed
Email:
Principal Investigator
Facility:
Name:
Sanford Cancer Center Oncology Clinic
Address:
City:
Sioux Falls
Zip:
57104
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
605-312-3320
Email:
OncologyClinicTrialsSF@sanfordhealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
Sanford USD Medical Center - Sioux Falls
Address:
City:
Sioux Falls
Zip:
57117-5134
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
605-312-3320
Email:
OncologyClinicalTrialsSF@SanfordHealth.org
Investigator:
Last name:
Daniel Almquist
Email:
Principal Investigator
Facility:
Name:
MD Anderson in The Woodlands
Address:
City:
Conroe
Zip:
77384
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
866-632-6789
Email:
askmdanderson@mdanderson.org
Investigator:
Last name:
Sunyoung Lee
Email:
Principal Investigator
Facility:
Name:
M D Anderson Cancer Center
Address:
City:
Houston
Zip:
77030
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-632-6789
Email:
askmdanderson@mdanderson.org
Investigator:
Last name:
Sunyoung Lee
Email:
Principal Investigator
Facility:
Name:
MD Anderson West Houston
Address:
City:
Houston
Zip:
77079
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-632-6789
Email:
askmdanderson@mdanderson.org
Investigator:
Last name:
Sunyoung Lee
Email:
Principal Investigator
Facility:
Name:
MD Anderson League City
Address:
City:
League City
Zip:
77573
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-632-6789
Email:
askmdanderson@mdanderson.org
Investigator:
Last name:
Sunyoung Lee
Email:
Principal Investigator
Facility:
Name:
MD Anderson in Sugar Land
Address:
City:
Sugar Land
Zip:
77478
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-632-6789
Email:
askmdanderson@mdanderson.org
Investigator:
Last name:
Sunyoung Lee
Email:
Principal Investigator
Facility:
Name:
Inova Schar Cancer Institute
Address:
City:
Fairfax
Zip:
22031
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
703-720-5210
Email:
Stephanie.VanBebber@inova.org
Investigator:
Last name:
Timothy L. Cannon
Email:
Principal Investigator
Facility:
Name:
Inova Fairfax Hospital
Address:
City:
Falls Church
Zip:
22042
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
703-208-6650
Email:
Stephanie.VanBebber@inova.org
Investigator:
Last name:
Timothy L. Cannon
Email:
Principal Investigator
Facility:
Name:
Virginia Cancer Institute
Address:
City:
Richmond
Zip:
23229
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
804-287-3000
Email:
smoore@vacancer.com
Investigator:
Last name:
Emily N. Kinsey
Email:
Principal Investigator
Facility:
Name:
VCU Massey Cancer Center at Stony Point
Address:
City:
Richmond
Zip:
23235
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
ctoclinops@vcu.edu
Investigator:
Last name:
Emily N. Kinsey
Email:
Principal Investigator
Facility:
Name:
Virginia Commonwealth University/Massey Cancer Center
Address:
City:
Richmond
Zip:
23298
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
CTOclinops@vcu.edu
Investigator:
Last name:
Emily N. Kinsey
Email:
Principal Investigator
Facility:
Name:
VCU Community Memorial Health Center
Address:
City:
South Hill
Zip:
23970
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
nemer.elmouallem@vcuhealth.org
Investigator:
Last name:
Emily N. Kinsey
Email:
Principal Investigator
Facility:
Name:
Swedish Cancer Institute-Edmonds
Address:
City:
Edmonds
Zip:
98026
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
206-215-3086
Email:
PCRC-NCORP@Swedish.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
Swedish Cancer Institute-Issaquah
Address:
City:
Issaquah
Zip:
98029
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
206-215-3086
Email:
PCRC-NCORP@Swedish.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
Valley Medical Center
Address:
City:
Renton
Zip:
98055
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
425-228-3440
Email:
research@valleymed.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
Swedish Medical Center-First Hill
Address:
City:
Seattle
Zip:
98122
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
206-215-3086
Email:
PCRC-NCORP@Swedish.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
West Virginia University Healthcare
Address:
City:
Morgantown
Zip:
26506
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
304-293-7374
Email:
cancertrialsinfo@hsc.wvu.edu
Investigator:
Last name:
Brian A. Boone
Email:
Principal Investigator
Facility:
Name:
Duluth Clinic Ashland
Address:
City:
Ashland
Zip:
54806
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Southern Lakes VLCC
Address:
City:
Burlington
Zip:
53105
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Saint Luke's South Shore
Address:
City:
Cudahy
Zip:
53110
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Health Care Germantown Health Center
Address:
City:
Germantown
Zip:
53022
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Grafton
Address:
City:
Grafton
Zip:
53024
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora BayCare Medical Center
Address:
City:
Green Bay
Zip:
54311
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Kenosha South
Address:
City:
Kenosha
Zip:
53142
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Bay Area Medical Group-Marinette
Address:
City:
Marinette
Zip:
54143
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Milwaukee
Address:
City:
Milwaukee
Zip:
53209
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Saint Luke's Medical Center
Address:
City:
Milwaukee
Zip:
53215
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Sinai Medical Center
Address:
City:
Milwaukee
Zip:
53233
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Vince Lombardi Cancer Clinic - Oshkosh
Address:
City:
Oshkosh
Zip:
54904
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Racine
Address:
City:
Racine
Zip:
53406
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Vince Lombardi Cancer Clinic-Sheboygan
Address:
City:
Sheboygan
Zip:
53081
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Medical Center in Summit
Address:
City:
Summit
Zip:
53066
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Vince Lombardi Cancer Clinic-Two Rivers
Address:
City:
Two Rivers
Zip:
54241
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Milwaukee West
Address:
City:
Wauwatosa
Zip:
53226
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora West Allis Medical Center
Address:
City:
West Allis
Zip:
53227
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Start date:
February 9, 2024
Completion date:
January 21, 2025
Lead sponsor:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Source:
National Cancer Institute (NCI)
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05564403
